Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 13/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686410 | 0.97 | CYP1A2 (0.54) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7679685 | 0.97 | KMT2A (0.50) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7681735 | 0.91 | KMT2A (0.48) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7675267 | 0.88 | CYP1A2 (0.44) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7685334 | 0.81 | HTT (0.43) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7681871 | 0.81 | HTT (0.50) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7681977 | 0.81 | CYP1A2 (0.40) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7679806 | 0.80 | CYP2C19 (0.40) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7684492 | 0.79 | CYP1A2 (0.38) | CYP1A2CYP2C19KMT2ACYP2C9GAA | |
| SCHEMBL7677782 | 0.79 | DAO (0.56) | KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889874-B2 | Imidazolone-chalcone derivatives as potential anticancer agent and process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2014-11-18 | — | — | US | disclosed |
| EP-2523941-B1 | IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2014-10-15 | — | — | EP | disclosed |
| US-20130066081-A1 | IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066081-A1 | IMIDAZOLONE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF | SIK1, SIK2, SIK3 | CYP1A2 619/4885CYP2C19 229/4885KMT2A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.